{"id":11260,"date":"2011-08-30T06:07:16","date_gmt":"2011-08-30T10:07:16","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&p=11260"},"modified":"2011-09-01T12:52:54","modified_gmt":"2011-09-01T16:52:54","slug":"new-results-from-emphasis-hf-show-big-benefits-for-high-risk-subgroups-taking-eplerenone","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/08\/30\/new-results-from-emphasis-hf-show-big-benefits-for-high-risk-subgroups-taking-eplerenone\/","title":{"rendered":"New Results from EMPHASIS-HF Show Big Benefits For High-Risk Subgroups Taking Eplerenone"},"content":{"rendered":"

Last November\u00a0the main results of the EMPHASIS-HF trial<\/a>\u00a0demonstrated that eplerenone was significantly better than placebo in reducing the risk for death and hospitalization in patients with systolic heart failure and mild symptoms. Now a new analysis of the trial,\u00a0presented by Bertram Pitt at the European Society of Cardiology meeting in Paris<\/a>, reinforces the earlier findings — and demonstrates an especially dramatic benefit in multiple high-risk subgroups.<\/p>\n

Because EMPHASIS-HF was terminated early for efficacy, there was a possibility that the observed effect seen in the trial might have been exaggerated. In some countries, however, where eplerenone was not commercially available, the blinded study continued. Pitt therefore showed the results for the primary endpoint for an additional 10 months, in which no discernible attenuation of effect was observed:<\/p>\n